Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2018, Article ID 1025893, 14 pages
https://doi.org/10.1155/2018/1025893
Review Article

Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review

1Faculty of Medicine, St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia
2Heart Failure and Transplant Unit, St Vincent’s Hospital, Sydney, NSW, Australia
3Victor Chang Cardiac Research Institute, Sydney, NSW, Australia
4Department of Endocrinology and Diabetes, St Vincent’s Hospital, Sydney, NSW, Australia
5Diabetes and Metabolism Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia

Correspondence should be addressed to Peter S. Macdonald; ua.gro.ahvs@dlanodcam.retep

Received 20 October 2017; Accepted 27 December 2017; Published 29 January 2018

Academic Editor: John Paul Scott

Copyright © 2018 Matthew G. Cehic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. H. Lund, L. B. Edwards, A. I. Dipchand et al., “The Registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report—2016; focus theme: primary diagnostic indications for transplant,” The Journal of Heart and Lung Transplantation, vol. 35, no. 10, pp. 1158–1169, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Cho, H.-I. Choi, I.-O. Kim et al., “The clinical course and outcomes of post-transplantation diabetes mellitus after heart transplantation,” Journal of Korean Medical Science, vol. 27, no. 12, pp. 1460–1467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Marelli, H. Laks, B. Patel et al., “Heart transplantation in patients with diabetes mellitus in the current era,” The Journal of Heart and Lung Transplantation, vol. 22, no. 10, pp. 1091–1097, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. V. M. Montori, A. Basu, P. J. Erwin, J. A. Velosa, S. E. Gabriel, and Y. C. Kudva, “Posttransplantation diabetes: a systematic review of the literature,” Diabetes Care, vol. 25, no. 3, pp. 583–592, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. R. Costanzo, A. Dipchand, R. Starling et al., “The international society of heart and lung transplantation guidelines for the care of heart transplant recipients,” The Journal of Heart and Lung Transplantation, vol. 29, no. 8, pp. 914–956, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Säemann and W. H. Hörl, “Urinary tract infection in renal transplant recipients,” European Journal of Clinical Investigation, vol. 38, no. 2, pp. 58–65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Sharif and S. Cohney, “Post-transplantation diabetes-state of the art,” The Lancet Diabetes & Endocrinology, vol. 4, no. 4, pp. 337–349, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Rana, A. Gruessner, V. G. Agopian et al., “Survival benefit of solid-organ transplant in the United States,” JAMA Surgery, vol. 150, no. 3, pp. 252–259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Starzl, T. Marchioro, D. Rifkind, J. Holmes, D. Rowlands Jr., and W. Waddell, “Factors in successful renal transplantation,” Surgery, vol. 56, 296 pages, 1964. View at Google Scholar
  10. J. Davidson, A. Wilkinson, J. Dantal et al., “New-onset diabetes after transplantation: 2003 International Consensus Guidelines - Proceedings of an International Expert Panel Meeting Barcelona, Spain 19 February 2003,” Transplantation, vol. 75, no. 10, pp. SS1–SS24, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Sharif, M. Hecking, A. P. J. De Vries et al., “Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions,” American Journal of Transplantation, vol. 14, no. 9, pp. 1992–2000, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Marchetti, “New-onset diabetes after transplantation,” The Journal of Heart and Lung Transplantation, vol. 23, no. 5, pp. S194–S201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Ye, H.-T. Kuo, M. Sampaio, Y. Jiang, P. Reddy, and S. Bunnapradist, “Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients,” Transplantation, vol. 89, no. 12, pp. 1526–1532, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Saraiva, E. Sola, D. Prieto, and M. J. Antunes, “Diabetes as an outcome predictor after heart transplantation,” Interactive CardioVascular and Thoracic Surgery, vol. 13, no. 5, pp. 499–504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Depczynski, B. Daly, L. V. Campbell, D. J. Chisholm, and A. Keogh, “Predicting the occurrence of diabetes mellitus in recipients of heart transplants,” Diabetic Medicine, vol. 17, no. 1, pp. 15–19, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. American Diabetes Association., “2. Classification and diagnosis of diabetes,” Diabetes Care, vol. 38, pp. S8–S16, 2015. View at Publisher · View at Google Scholar
  17. World Health Organization., “Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO consultation, Geneva: World Health Organization, (2006)”.
  18. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2072–2077, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. B. Green, M. A. Bethel, and P. W. Armstrong, “Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes,” The New England Journal of Medicine, vol. 373, no. 3, pp. 232–242, 2015. View at Publisher · View at Google Scholar
  21. F. Zannad, C. P. Cannon, W. C. Cushman et al., “Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial,” The Lancet, vol. 385, no. 9982, pp. 2067–2076, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., “Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 369, no. 14, pp. 1317–1326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. P. Marso, G. H. Daniels, K. B. Frandsen et al., “Liraglutide and cardiovascular outcomes in type 2 diabetes,” The New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. S. P. Marso, S. C. Bain, and A. Consoli, “Semaglutide and cardiovascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 375, no. 19, pp. 1834–1844, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Zinman, C. Wanner, J. M. Lachin et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” The New England Journal of Medicine, vol. 373, no. 22, pp. 2117–2128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. “The Transplantation Society of Australia and New Zealand Clinical Guidelines for Organ Transplantation from Deceased Donors, (2016)”.
  27. M. J. Russo, J. M. Chen, K. N. Hong et al., “Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus,” Circulation, vol. 114, no. 21, pp. 2280–2287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Midtvedt, J. Hjelmesæth, A. Hartmann et al., “Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3233–3239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Hecking, J. Werzowa, M. Haidinger et al., “Novel views on new-onset diabetes after transplantation: development, prevention and treatment, Nephrology, dialysis,” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, vol. 28, pp. 550–566, 2013. View at Google Scholar
  30. M. Hecking, A. Kainz, J. Werzowa et al., “Glucose metabolism after renal transplantation,” Diabetes Care, vol. 36, no. 9, pp. 2763–2771, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Midtvedt, A. Hartmann, J. Hjelmesæth, K. Lund, and B. L. Bjerkely, “Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients,” Nephrology Dialysis Transplantation , vol. 13, no. 2, pp. 427–431, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. Weir and J. C. Fink, “Risk for posttransplant diabetes mellitus with current immunosuppressive medications,” American Journal of Kidney Diseases, vol. 34, no. 1, pp. 1–13, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. P.-T. T. Pham, P.-C. T. Pham, G. S. Lipshutz, and A. H. Wilkinson, “New onset diabetes mellitus after solid organ transplantation,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 4, pp. 873–890, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. C. J. Yates, S. Fourlanos, J. Hjelmesæth, P. G. Colman, and S. J. Cohney, “New-onset diabetes after kidney transplantation - Changes and challenges,” American Journal of Transplantation, vol. 12, no. 4, pp. 820–828, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the european association for the study of diabetes,” Diabetes Care, vol. 38, pp. 140–149, 2015. View at Publisher · View at Google Scholar
  36. D. H. Van Raalte, D. M. Ouwens, and M. Diamant, “Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 81–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. T. Mathew, M. Rao, V. Job, S. Ratnaswamy, and C. K. Jacob, “Post-transplant hyperglycaemia: A study of risk factors,” Nephrology Dialysis Transplantation , vol. 18, no. 1, pp. 164–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. J. D. Pirsch, A. K. Henning, M. R. First et al., “New-onset diabetes after transplantation: Results from a double-blind early corticosteroid withdrawal trial,” American Journal of Transplantation, vol. 15, no. 7, pp. 1982–1990, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Subramanian and D. L. Trence, “Immunosuppressive agents: effects on glucose and lipid metabolism,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 4, pp. 891–905, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill, “Sirolimus is associated with new-onset diabetes in Kidney transplant recipients,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1411–1418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. M. Flechner, M. Glyda, S. Cockfield et al., “The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients,” American Journal of Transplantation, vol. 11, no. 8, pp. 1633–1644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. P. Carroll, J. Hester, K. J. Wood, and P. N. Harden, “Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype,” Nephrology Dialysis Transplantation , vol. 28, no. 2, pp. 462–465, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Murakami, L. V. Riella, and T. Funakoshi, “Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: A systematic review and meta-analysis,” American Journal of Transplantation, vol. 14, no. 10, pp. 2317–2327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. D. Barlow, M. L. Nicholson, and T. P. Herbert, “Evidence for rapamycin toxicity in pancreatic β-Cells and a review of the underlying molecular mechanisms,” Diabetes, vol. 62, no. 8, pp. 2674–2682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. J. L. Larsen, R. G. Bennett, T. Burkman et al., “Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats,” Transplantation, vol. 82, no. 4, pp. 466–470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-M. Luo, N.-K. Chou, N.-H. Chi et al., “The effect of statins on cardiac allograft survival,” Transplantation Proceedings, vol. 46, no. 3, pp. 920–924, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Vallakati, S. Reddy, M. E. Dunlap, and D. O. Taylor, “Impact of statin use after heart transplantation,” Circulation: Heart Failure, vol. 9, no. 10, Article ID e003265, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Sattar, D. Preiss, and H. M. Murray, “Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials,” The Lancet, vol. 375, no. 9716, pp. 734–742, 2010. View at Publisher · View at Google Scholar
  49. H. A. Chakkera, E. J. Weil, J. Castro et al., “Hyperglycemia during the immediate period after kidney transplantation,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 4, pp. 853–859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. C. Thomas, T. H. Mathew, G. R. Russ, M. M. Rao, and J. Moran, “Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: A pilot study,” Transplantation, vol. 72, no. 7, pp. 1321–1324, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Hecking, M. Haidinger, D. Döller et al., “Early basal insulin therapy decreases new-onset diabetes after renal transplantation,” Journal of the American Society of Nephrology, vol. 23, no. 4, pp. 739–749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. K. L. Hermayer, M. F. Egidi, N. J. Finch et al., “A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 12, pp. 4399–4406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Garcia, A. Wallia, S. Gupta et al., “Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients,” Clinical Transplantation, vol. 27, no. 3, pp. 444–454, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Ikeda, G. Tenderich, A. Zittermann, K. Minami, and R. Koerfer, “Heart transplantation in insulin-treated diabetic mellitus patients with diabetes-related complications,” Transplant International, vol. 20, no. 6, pp. 528–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Bedanova, J. Ondrasek, J. Cerny et al., “Impact of diabetes mellitus on survival rates after heart transplantation,” Biomedical Papers, vol. 153, no. 4, pp. 283–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Higgins, P. W. Pflugfelder, and W. J. Kostuk, “Increased morbidity in diabetic cardiac transplant recipients,” Canadian Journal of Cardiology, vol. 25, no. 4, pp. e125–e129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. American Diabetes Association, “Standards of medical care in diabetes - 2017,” Journal of Diabetes, vol. 40, no. 7, pp. s1–s135, 2017. View at Publisher · View at Google Scholar
  58. A. Wallia, V. Illuri, and M. E. Molitch, “Diabetes Care after transplant: Definitions, risk factors, and clinical management,” Medical Clinics of North America, vol. 100, no. 3, pp. 535–550, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. S. R. Salpeter, N. S. Buckley, J. A. Kahn, and E. E. Salpeter, “Meta-analysis: metformin treatment in persons at risk for diabetes mellitus,” American Journal of Medicine, vol. 121, no. 2, pp. 149–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Kurian, R. Joshi, and A. Helmuth, “Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients,” Endocrine Practice, vol. 14, no. 8, pp. 979–984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. S. E. Inzucchi, K. J. Lipska, H. Mayo, C. J. Bailey, and D. K. McGuire, “Metformin in patientswith type 2 diabetes and kidney disease: a systematic review,” The Journal of the American Medical Association, vol. 312, no. 24, pp. 2668–2675, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Salpeter, E. Greyber, G. Pasternak, and E. Salpeter, “Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 2, 2010. View at Google Scholar
  64. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304-1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Mamtani, N. Pfanzelter, K. Haynes et al., “Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas,” Diabetes Care, vol. 37, no. 7, pp. 1910–1917, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. F. M. Ashcroft, “Mechanisms of the clycaemic effects of sulfonylureas,” Hormone and Metabolic Research, vol. 28, no. 9, pp. 456–463, 1996. View at Publisher · View at Google Scholar · View at Scopus
  67. I. W. Campbell, “Sulfonylureas and hypoglycemia,” Diabetic Hypoglycemia, vol. 2, pp. 3–10, 2009. View at Publisher · View at Google Scholar
  68. M. Haidinger, M. Antlanger, C. Kopecky, J. J. Kovarik, M. D. Säemann, and J. Werzowa, “Post-transplantation diabetes mellitus: Evaluation of treatment strategies,” Clinical Transplantation, vol. 29, no. 5, pp. 415–424, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Türk, F. Pietruck, S. Dolff et al., “Repaglinide in the management of new-onset diabetes mellitus after renal transplantation,” American Journal of Transplantation, vol. 6, no. 4, pp. 842–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. K. M. Pantalone, M. W. Kattan, C. Yu et al., “The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: A retrospective analysis,” Diabetes Care, vol. 33, no. 6, pp. 1224–1229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Monami, S. Genovese, and E. Mannucci, “Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials,” Diabetes, Obesity and Metabolism, vol. 15, no. 10, pp. 938–953, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Yki-Järvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Miyazaki, M. Matsuda, and R. A. DeFronzo, “Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes,” Diabetes Care, vol. 25, no. 3, pp. 517–523, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. S. N. Nowak, D. J. Edwards, A. Clarke, G. D. Anderson, and L. A. Jaber, “Pioglitazone: Effect on CYP3A4 activity,” Clinical Pharmacology and Therapeutics, vol. 42, no. 12, pp. 1299–1302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. A. N. Jacob, K. Salinas, B. Adams-Huet, and P. Raskin, “Weight gain in type 2 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 386–393, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Raskin, M. Rendell, M. C. Riddle, J. F. Dole, M. I. Freed, and J. Rosenstock, “A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes,” Diabetes Care, vol. 24, no. 7, pp. 1226–1232, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Balas, R. Belfort, S. A. Harrison et al., “Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 47, no. 4, pp. 565–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Füchtenbusch, E. Standl, and H. Schatz, “Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus,” Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 3, pp. 151–163, 2000. View at Publisher · View at Google Scholar · View at Scopus
  79. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and American diabetes association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” The Lancet, vol. 373, no. 9681, pp. 2125–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. D. J. Graham, R. Ouellet-Hellstrom, T. E. Macurdy et al., “Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone,” Journal of the American Medical Association, vol. 304, no. 4, pp. 411–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Dormandy, M. Bhattacharya, and A.-R. Van Troostenburg De Bruyn, “Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive,” Drug Safety, vol. 32, no. 3, pp. 187–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. C. R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J. M. Wright, “Thiazolidinediones and fractures in men and women,” JAMA Internal Medicine, vol. 169, no. 15, pp. 1395–1402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. Z. A. Habib, S. L. Havstad, K. Wells, G. Divine, M. Pladevall, and L. K. Williams, “Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 2, pp. 592–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Kermode-Scott, “Meta-analysis confirms raised risk of bladder cancer from pioglitazone,” British Medical Journal, vol. 345, Article ID e4541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Neumann, A. Weill, P. Ricordeau, J. P. Fagot, F. Alla, and H. Allemand, “Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study,” Diabetologia, vol. 55, no. 7, pp. 1953–1962, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Mcintyre, C. D. Holdsworth, and D. S. Turner, “New interpretation of oral glucose tolerance,” The Lancet, vol. 284, no. 7349, pp. 20-21, 1964. View at Google Scholar · View at Scopus
  89. H. Elrick, L. Stimmler, C. Hlad Jr., and Y. Arai, “Plasma Insulin Response to Oral and Intravenous Glucose Administration 1,” The Journal of Clinical Endocrinology & Metabolism, vol. 24, pp. 1076–1082, 1964. View at Google Scholar
  90. M. A. Nauck, “Unraveling the science of incretin biology,” European Journal of Internal Medicine, vol. 20, no. 2, pp. S303–S308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Morales, “The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors,” Postgraduate Medical Journal, vol. 123, no. 6, pp. 189–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. P. C. Butler, M. Elashoff, R. Elashoff, and E. A. M. Gale, “A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?” Diabetes Care, vol. 36, no. 7, pp. 2118–2125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. J. A. Lovshin and D. J. Drucker, “Incretin-based therapies for type 2 diabetes mellitus,” Nature Reviews Endocrinology, vol. 5, no. 5, pp. 262–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. R. E. Amori, J. Lau, and A. G. Pittas, “Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis,” Journal of the American Medical Association, vol. 298, no. 2, pp. 194–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. N. R. Pinelli, A. Patel, and F. D. Salinitri, “Coadministration of liraglutide with tacrolimus in kidney transplant recipients: A case series,” Diabetes Care, vol. 36, no. 10, pp. e171–e172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Cariou, C. Bernard, and D. Cantarovich, “Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series,” Diabetes & Metabolism, vol. 41, no. 3, pp. 252–257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. B. P. Boerner, C. D. Miles, and V. Shivaswamy, “Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation,” International Journal of Endocrinology, vol. 2014, Article ID 617638, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Werzowa, M. Hecking, M. Haidinger et al., “Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: A randomized, placebo-controlled clinical trial,” Transplantation, vol. 95, no. 3, pp. 456–462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. I. Gueler, S. Mueller, M. Helmschrott et al., “Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation,” Drug Design, Development and Therapy, vol. 7, pp. 297–303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. A. J. Scheen, “Erratum: Dipeptidylpeptidase-4 inhibitors (gliptins),” Clinical Pharmacokinetics, vol. 49, no. 9, pp. 573–588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Amin and N. Suksomboon, “Pharmacotherapy of type 2 diabetes mellitus: An update on drug–drug interactions,” Drug Safety, vol. 37, no. 11, pp. 903–919, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. U. Graefe-Mody, C. Friedrich, A. Port et al., “Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin,” Diabetes, Obesity and Metabolism, vol. 13, no. 10, pp. 939–946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Lukashevich, A. Schweizer, Q. Shao, P.-H. Groop, and W. Kothny, “Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial,” Diabetes, Obesity and Metabolism, vol. 13, no. 10, pp. 947–954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. J. C. Arjona Ferreira, D. Corry, C. E. Mogensen et al., “Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial,” American Journal of Kidney Diseases, vol. 61, no. 4, pp. 579–587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. H. Linnebjerg, P. A. Kothare, S. Park et al., “Effect of renal impairment on the pharmacokinetics of exenatide,” British Journal of Clinical Pharmacology, vol. 64, no. 3, pp. 317–327, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. L. V. Jacobsen, C. Hindsberger, R. Robson, and M. Zdravkovic, “Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide,” British Journal of Clinical Pharmacology, vol. 68, no. 6, pp. 898–905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Li, J. Shen, M. M. Bala et al., “Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies,” British Medical Journal, vol. 348, Article ID g2366, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. A. G. Egan, E. Blind, K. Dunder et al., “Pancreatic safety of incretin-based drugs—FDA and EMA assessment,” The New England Journal of Medicine, vol. 370, no. 9, pp. 794–797, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. R. W. Thomsen, L. Pedersen, N. Møller, J. Kahlert, H. Beck-Nielsen, and H. T. Sørensen, “incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study,” Diabetes Care, 2015. View at Publisher · View at Google Scholar
  111. L. W. Madsen, J. A. Knauf, C. Gotfredsen et al., “GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation,” Endocrinology, vol. 153, no. 3, pp. 1538–1547, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. D. Cohen, “Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?” British Medical Journal, vol. 346, no. 7912, Article ID f3680, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. R. K. Campbell, M. E. Cobble, T. S. Reid, and M. E. Shomali, “Safety, tolerability, and nonglycemic effects of incretin-based therapies,” Journal of Family Practice, vol. 59, no. 9, pp. S20–S27, 2010. View at Google Scholar · View at Scopus
  114. J. H. Helderman and S. Goral, “Gastrointestinal complications of transplant immunosuppression,” Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 277–287, 2002. View at Google Scholar · View at Scopus
  115. S. Ravassa, A. Zudaire, and J. Díez, “GLP-1 and cardioprotection: From bench to bedside,” Cardiovascular Research, vol. 94, no. 2, pp. 316–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. J. A. Kobashigawa, R. C. Starling, M. R. Mehra et al., “Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients,” The Journal of Heart and Lung Transplantation, vol. 25, no. 9, pp. 1063–1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. W. B. White, C. P. Cannon, S. R. Heller et al., “Alogliptin after acute coronary syndrome in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 369, no. 14, pp. 1327–1335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. R. K. Ghosh, S. M. Ghosh, S. Chawla, and S. A. Jasdanwala, “SGLT2 inhibitors: A new emerging therapeutic class in the treatment of type 2 diabetes mellitus,” Clinical Pharmacology and Therapeutics, vol. 52, no. 4, pp. 457–463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Heise, E. Seewaldt-Becker, S. Macha et al., “Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 15, no. 7, pp. 613–621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Perseghin and A. Solini, “The EMPA-REG outcome study: Critical appraisal and potential clinical implications,” Cardiovascular Diabetology, vol. 15, no. 1, article no. 85, 2016. View at Publisher · View at Google Scholar · View at Scopus
  121. B. Neal, V. Perkovic, and K. W. Mahaffey, “Canagliflozin and cardiovascular and renal events in type 2 diabetes,” The New England Journal of Medicine, 2017. View at Publisher · View at Google Scholar
  122. C. Wanner, S. E. Inzucchi, J. M. Lachin et al., “Empagliflozin and progression of kidney disease in type 2 diabetes,” The New England Journal of Medicine, vol. 375, no. 4, pp. 323–334, 2016. View at Publisher · View at Google Scholar · View at Scopus
  123. C. A. Muir, J. R. Greenfield, and P. S. MacDonald, “Empagliflozin in the management of diabetes mellitus after cardiac transplantation,” The Journal of Heart and Lung Transplantation, 2017. View at Google Scholar
  124. A. L. Peters, E. O. Buschur, J. B. Buse, P. Cohan, J. C. Diner, and I. B. Hirsch, “Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition,” Diabetes Care, vol. 38, no. 9, pp. 1687–1693, 2015. View at Publisher · View at Google Scholar